PL EN


Preferences help
enabled [disable] Abstract
Number of results
Journal
2011 | 6 | 6 | 778-782
Article title

Complete remission of primary bilateral adrenal lymphoma achieved by Rituximab-CHOP chemotherapy

Content
Title variants
Languages of publication
EN
Abstracts
EN
Primary adrenal lymphoma (PAL) is an exceedingly rare disease. Because of its rareness, uncertain etiology, variable duration of survival, unremarkable clinical presentations and unsatisfied therapeutic strategies, its treatment has always been unsatisfactory. Here we report a 50-year-old male patient with primary bilateral adrenal diffuse large B-cell lymphoma. He was treated with surgery followed by combined chemotherapy using R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone). He achieved complete remission after 3 cycles of chemotherapy. At present, he is considered free of tumor at 3 years after chemotherapy. Our case report demonstrates that patients with primary bilateral adrenal diffuse large B-cell lymphoma may achieve a good outcome using R-CHOP chemotherapy. To the best of our knowledge, our patient who achieved complete remission after R-CHOP chemotherapy has had the longest survival as published in the literature.
Publisher

Journal
Year
Volume
6
Issue
6
Pages
778-782
Physical description
Dates
published
1 - 12 - 2011
online
8 - 10 - 2011
Contributors
author
  • Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, Zhejiang Province, China, lancetyang@yahoo.com.cn
author
  • Department of Endocrinology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, Zhejiang Province, China
author
  • Department of Medicine, The First Clinical Medical Institute of Wenzhou Medical College, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, Zhejiang Province, China
author
  • Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, Zhejiang Province, China
author
  • Department of Medical Oncology, Cancer Hospital, Fudan University, Shanghai, 200000, China
author
  • Department of Pathology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, Zhejiang Province, China
author
  • Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, Zhejiang Province, China
  • Department of Oncology, The First Affiliated Hospital of Wenzhou Medical College, Wenzhou, 325000, Zhejiang Province, China
References
  • [1] Ozimek A, Diebold J, Linke R, et al. Bilateral primary adrenal non-Hodgkin’s lymphoma and primary adrenocortical carcinoma-review of the literature preoperative differentiation of adrenal tumors. Endocr J 2008;55: 625–638 http://dx.doi.org/10.1507/endocrj.K08E-035[WoS][Crossref]
  • [2] Wang JP, Sun HR, Li YJ, et al. Imaging features of primary adrenal lymphoma. Chin Med J (Engl) 2009;122: 2516–2520
  • [3] Nishiuchi T, Imachi H, Fujiwara M, et al. A case of non-Hodgkin’s lymphoma primary arising in both adrenal glands associated with adrenal failure. Endocrine 2009;35: 34–37 http://dx.doi.org/10.1007/s12020-008-9125-3[WoS][Crossref]
  • [4] Mantzios G, Tsirigotis P, Veliou F, et al. Primary adrenal lymphoma presenting as Addison’s disease: case report and review of the literature. Ann Hematol 2004;83:460–463 http://dx.doi.org/10.1007/s00277-003-0838-3[Crossref]
  • [5] Kumar R, Xiu Y, Mavi A, et al. FDG-PET imaging in primary bilateral adrenal lymphoma: a case report and review of the literature. Clin Nucl Med 2005;30: 222–230 http://dx.doi.org/10.1097/01.rlu.0000155983.46815.1c[Crossref]
  • [6] Tomoyose T, Nagasaki A, Uchihara JN, et al. Primary adrenal adult T-cell leukemia/lymphoma: a case report and review of the literature. Am J Hematol 2007;82: 748–752 http://dx.doi.org/10.1002/ajh.20856[Crossref]
  • [7] Alvarez-Castells A, Pedraza S, Tallada N, et al. CT of primary bilateral adrenal lymphoma. J Comput Assist Tomogr 1993;17: 408–409 http://dx.doi.org/10.1097/00004728-199305000-00013[Crossref]
  • [8] Serrano S, Tejedor L, Garcia B, et al. Addisonian crisis as the presenting feature of bilateral primary adrenal lymphoma. Cancer 1993;71: 4030–4033 http://dx.doi.org/10.1002/1097-0142(19930615)71:12<4030::AID-CNCR2820711237>3.0.CO;2-Q[Crossref]
  • [9] Grigg AP, Connors JM. Primary adrenal lymphoma. Clin Lymphoma 2003;4: 154–160 http://dx.doi.org/10.3816/CLM.2003.n.024[Crossref]
  • [10] Mori M, Kitamura K, Masuda M, et al. Long-term results of a multicenter randomized, comparative trial of modified CHOP versus THP-COP versus THPCOPE regimens in elderly patients with non-Hodgkin’s lymphoma. Int J Hematol 2005;81:246–254 http://dx.doi.org/10.1532/IJH97.03147[Crossref]
  • [11] Keating GM. Rituximab: a review of its use in chronic lymphocytic leukaemia, low-grade or follicular lymphoma and diffuse large B-cell lymphoma. Drugs 2010;70:1445–1476 http://dx.doi.org/10.2165/11201110-000000000-00000[Crossref][WoS]
  • [12] Pfreundschuh M, Trümper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006;7:379–391 http://dx.doi.org/10.1016/S1470-2045(06)70664-7[Crossref]
  • [13] Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346:235–242 http://dx.doi.org/10.1056/NEJMoa011795[Crossref]
  • [14] Colovic N, Jurisic V, Terzic T, et al. Immunochemotherapy for Bcl-2 and MUM-negative aggressive primary cutaneous B-cell non-Hodgkin’s lymphoma. Arch Dermatol Res 2009;301:689–692 http://dx.doi.org/10.1007/s00403-009-0967-1[Crossref][WoS]
  • [15] Shirao S, Kuroda H, Kida M, et al. [Effective combined modality therapy for a patient with primary adrenal lymphoma]. Rinsho Ketsueki 2006;47: 204–209
  • [16] Kim KM, Yoon DH, Lee SG, et al. A case of primary adrenal diffuse large B-cell lymphoma achieving complete remission with rituximab-CHOP chemotherapy. J Korean Med Sci 2009;24: 525–528 http://dx.doi.org/10.3346/jkms.2009.24.3.525[WoS][Crossref]
Document Type
Publication order reference
Identifiers
YADDA identifier
bwmeta1.element.-psjd-doi-10_2478_s11536-011-0090-5
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.